Retatrutide

01 · What is it?

The identity comes first.

Retatrutide is an engineered peptide studied for its interaction with three metabolic hormone receptors. It combines GIP, GLP-1 and glucagon receptor activity in one molecule. A promising trial result is not a regulatory approval.

Scientific classification: Investigational peptide; triple receptor agonist

For example. Imagine a coordinated message reaching three departments, each with a different metabolic job.

02 · How does it work?

The signal, explained.

It activates three metabolic receptors. Two connect with meal-related signaling; the third adds a message involved in liver fuel handling. Researchers measure the combined result rather than assuming that each pathway simply adds a benefit.

The key research focus is GIP, GLP-1 and glucagon receptors. A target describes where an interaction may occur; it does not by itself establish a benefit.

03 · What happens after the signal?

Follow the downstream effects.

Incretin signaling influences insulin release and food intake; glucagon signaling influences liver glucose handling and potentially energy expenditure. Their net effect is a balance of pathways, not three independently guaranteed benefits.

To connect this mechanism to a real-world outcome, researchers need to establish exposure at the target, measure the response and test whether the change matters in a controlled human study.

04 · What is it commonly researched for?

The questions researchers are asking.

Researchers have investigated body weight, glucose regulation, sleep apnea, osteoarthritis-related outcomes and cardiometabolic endpoints.

These are areas of investigation, not promises about a Maison product.

05 · Body systems involved

Where the biology connects.

Pancreas

Participates in insulin, glucagon and meal-related hormone signaling.

Brain

Relevant to neural signaling, appetite, behavior or stress circuitry described above.

Liver

A central site of nutrient handling, metabolic enzymes and selected downstream hormone responses.

Adipose tissue

Relevant to lipid storage, mobilization and energy-balance research.

06 · Receptor / target profile

The molecular reference card.

Primary receptor or target

GIP, GLP-1 and glucagon receptors

Secondary interactions

No additional primary target established for the research claim discussed.

Where it is found

Pancreatic and neural incretin targets; glucagon receptors prominently in the liver.

Activation, inhibition or interaction

These class B G-protein-coupled receptors can activate Gs/cAMP pathways. Glucagon-receptor activity adds hepatic metabolic signaling to incretin-related pancreatic and neural effects.

Important downstream pathways

Incretin signaling influences insulin release and food intake; glucagon signaling influences liver glucose handling and potentially energy expenditure. Their net effect is a balance of pathways, not three independently guaranteed benefits.

07 · Evidence quality

What carries weight—and what does not.

A familiar mechanism, a patent, a testimonial or a trial registration alone cannot establish human efficacy or product quality.

08 · Who is studying it?

Follow the original research.

Eli Lilly and Company

Development name: LY3437943

Program: TRIUMPH (obesity and related outcomes); TRANSCEND-T2D (type 2 diabetes)

Development phase: Phase 3

Example trial record: NCT05929066

Registry status when checked: Completed enrollment on Lilly Trials at review; TRIUMPH-1 results reported in May 2026.

Regulatory context: United States: retatrutide is not a component of an FDA-approved drug. It remains investigational. Regulatory source checked October 9, 2026.

Registry links may include related compounds or historical studies. Read the exact intervention, sponsor, phase and latest update date. Recruitment status is specific to each trial.

09 · Research terminology

A small glossary for this page.

Explore the complete foundations glossary

10 · Research status & limitations

Keep the boundaries visible.

United States: retatrutide is not a component of an FDA-approved drug. It remains investigational. Regulatory source checked October 9, 2026.

Long-term outcomes, comparative benefit, clinically meaningful effects and safety for broad wellness use are not well established.

The main evidence category here is human clinical research. The exact molecule, formulation, study population and endpoint matter. Scientific evidence changes; this page is a dated educational summary, not continuous trial monitoring.